XSHG
603351
Market cap506mUSD
Jul 09, Last price
25.36CNY
1D
-2.08%
1Q
-2.01%
IPO
-18.56%
Name
Nanjing Well Pharmaceutical Co Ltd
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Nanjing Well Pharmaceutical Group Co., Ltd., founded in 2000 and headquartered in Nanjing, China, is primarily engaged in the research, development, manufacturing, and distribution of pharmaceutical excipients within the Chinese market. These essential auxiliary materials are utilized in both injectable and non-injectable drug formulations. Beyond its pharmaceutical focus, the company also supplies an extensive range of synthetic base oils for various industrial applications, including hydraulic fluids, lubricity additives for metals, metal quenching agents, compression lubricants, gear oils, chain lubricants, and base stocks for engine oils, heat transfer oils, and greases. Furthermore, its product portfolio diversifies into other specialized chemicals such as paints and coatings, textile chemicals, field chemicals, and low-foam metal cleaners. The company boasts a global presence, exporting its products to key markets in Europe, the United States, Southeast Asia, and other international regions. Originally known as Nanjing Well Pharmaceutical Co., Ltd., the company officially adopted its current name, Nanjing Well Pharmaceutical Group Co., Ltd., in April 2020.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||